Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.

PMID:
21516030
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.

Montague TH, Potvin D, Diliberti CE, Hauck WW, Parr AF, Schuirmann DJ.

Pharm Stat. 2012 Jan-Feb;11(1):8-13. doi: 10.1002/pst.483. Epub 2011 Feb 10.

PMID:
21308974
[PubMed - indexed for MEDLINE]
3.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.

PMID:
20554713
[PubMed - indexed for MEDLINE]
4.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
[PubMed - indexed for MEDLINE]
5.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.

PMID:
18690162
[PubMed - indexed for MEDLINE]
6.

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

N Engl J Med. 2007 Dec 6;357(23):2359-70.

PMID:
18057338
[PubMed - indexed for MEDLINE]
Free Article
7.

Sequential design approaches for bioequivalence studies with crossover designs.

Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA.

Pharm Stat. 2008 Oct-Dec;7(4):245-62.

PMID:
17710740
[PubMed - indexed for MEDLINE]
8.

Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects.

Marier JF, Lor M, Potvin D, Dimarco M, Morelli G, Saedder EA.

J Clin Pharmacol. 2006 Jun;46(6):642-53.

PMID:
16707411
[PubMed - indexed for MEDLINE]
9.

Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man.

Labbé L, Robitaille NM, Lefez C, Potvin D, Gilbert M, O'Hara G, Turgeon J.

Ther Drug Monit. 2004 Oct;26(5):492-8.

PMID:
15385831
[PubMed - indexed for MEDLINE]
10.

A qualitative study of attitudes toward error in patients facing brain tumour surgery.

Bernstein M, Potvin D, Martin DK.

Can J Neurol Sci. 2004 May;31(2):208-12.

PMID:
15198445
[PubMed - indexed for MEDLINE]
11.

Carry-over effects in bioequivalence studies.

Dangelo G, Potvin D, Turgeon J.

J Biopharm Stat. 2001 Feb-May;11(1-2):35-43.

PMID:
11459441
[PubMed - indexed for MEDLINE]
12.

Numerical methods for the evaluation of individual bioequivalence criteria.

Kimanani EK, Lavigne J, Potvin D.

Stat Med. 2000 Oct 30;19(20):2775-95.

PMID:
11033575
[PubMed - indexed for MEDLINE]
13.

Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.

Lalonde RL, Ouellet D, Kimanani EK, Potvin D, Vaughan LM, Hill MR.

J Pharmacokinet Biopharm. 1999 Feb;27(1):67-83.

PMID:
10533698
[PubMed - indexed for MEDLINE]
14.

Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation.

Gauthier-Gagnon C, Grisé MC, Potvin D.

Arch Phys Med Rehabil. 1999 Jun;80(6):706-13.

PMID:
10378500
[PubMed - indexed for MEDLINE]
15.

Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.

Gaudreault J, Potvin D, Lavigne J, Lalonde RL.

Pharm Res. 1998 Oct;15(10):1621-9.

PMID:
9794507
[PubMed - indexed for MEDLINE]
16.

A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence.

Kimanani EK, Potvin D.

J Pharmacokinet Biopharm. 1997 Oct;25(5):595-614.

PMID:
9679224
[PubMed - indexed for MEDLINE]
17.

Multistage designs for phase II clinical trials: statistical issues in cancer research.

Kramar A, Potvin D, Hill C.

Br J Cancer. 1996 Oct;74(8):1317-20. Review.

PMID:
8883425
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Research design for patient selection in clinical trials phase II].

Kramar A, Potvin D, Hill C.

Rev Epidemiol Sante Publique. 1996 Aug;44(4):364-71. French.

PMID:
8927779
[PubMed - indexed for MEDLINE]
19.

Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.

Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J.

Pediatrics. 1996 May;97(5):619-28.

PMID:
8628597
[PubMed - indexed for MEDLINE]
20.

Factors associated with length of survival among 1081 terminally ill cancer patients.

Allard P, Dionne A, Potvin D.

J Palliat Care. 1995 Autumn;11(3):20-4.

PMID:
7472787
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk